Microbiome Therapeutics Market Revenue to Attain USD 2547.49 Mn by 2033

01 Oct 2025

Share :

Table of Content

1. Microbiome Therapeutics Market Revenue and Trends 2025 to 2033 2. Factors Contributing to the Expansion of Radiation-Hardened Electronics 3. Segmental Analysis 4. Regional Analysis 5. Microbiome Therapeutics Market Coverage 6. Microbiome Therapeutics Market Key Players

Microbiome Therapeutics Market Revenue and Trends 2025 to 2033

The global microbiome therapeutics market revenue reached USD 250.06 million in 2025 and is predicted to attain around USD 2547.49 million by 2033 with a CAGR of 33.67%. The microbiome therapeutics market is driven by rising demand for personalized medicine, gastrointestinal treatments, and advancements in microbiome-based drug development.

Factors Contributing to the Expansion of Radiation-Hardened Electronics

The microbiome therapeutics market is witnessing significant growth driven by increasing awareness of gut health, chronic disease management and developments in microbiome based drug development. Microbiome therapeutics are one or products that modify the human microbiota to improve health outcomes. The market is seeing growth from pharmaceutical and biotech companies who are investing heavily to develop novel innovative therapies for digestive, metabolic and immune disorders.

Segmental Analysis

• By Type of Product - Probiotics Probiotics are leading the pack as they are the most commonly used for gut health maintenance and immunity, have good clinical validity, and are generally accepted by consumers for therapeutic and preventative use.
• By Therapeutic Application - Gastrointestinal Disorders Gastrointestinal disorders are leading the pack because most microbiome-based therapies and clinical studies that have been commercialized focus on treating irritable bowel syndrome, ulcerative colitis, and recurrent Clostridium difficile infections.
• By Mode of Administration - Oral Oral routes of administration dominate product development, which largely is based on patient convenience, ease of formulation, and effectiveness for both gastrointestinal and systemic benefits for probiotics, and live biotherapeutics.
• By End-user - Hospitals & Specialty Clinics Hospitals and specialty clinics prevail as primary locations for microbiome therapies, and this area is particularly popular for fecal microbiota transplantation (FMT) therapies and any prescription-based treatments requiring medical oversight and advanced clinical infrastructure.

Regional Analysis

North America leads the microbiome therapeutics market stemming from strong biopharma investment, established regulatory pathways, and concentrated clinical-trial infrastructure.  The U.S. is at the forefront with large established biotech clusters and extensive venture funding and adoption in hospitals and research centers expediting the commercialization of fecal transplants, live biotherapeutics development and active startup ecosystems for translation to market.

Asia Pacific is poised to be the fastest growing market, given rising healthcare expenditure, increasing clinical-trial capacity and regulatory modernization to speed up microbiome R&D.  China, Japan and India are scaling patient recruitment, local manufacturing, and public-private partnerships to enable rapid pipeline expansion and early access programs across infections, metabolic and oncology indication, facilitated by local funding and pilot regulatory schemes.

Microbiome Therapeutics Market Coverage

Recent Developments

• In June 2025, BioAro launches AI-driven omics-to-therapeutics platform which includes multilingual clinical reporting and an AI-powered deep drug discovery module in beta, establishing it as the first comprehensive, scalable omics-to-therapeutics solution. (Source: https://firstwordpharma.com)

Microbiome Therapeutics Market Key Players

• Seres Therapeutics, Inc. 
• Rebiotix (Ferring Pharmaceuticals) 
• Enterome SA 
• 4D Pharma plc 
• Vedanta Biosciences, Inc. 
• Finch Therapeutics Group, Inc. 
• Second Genome 
• Synlogic, Inc. 
• Microbiotica Ltd. 
• Axial Therapeutics, Inc. 
• AOBiome Therapeutics 
• Evelo Biosciences, Inc. 
• MaaT Pharma 
• Quorum Innovations 
• Novome Biotechnologies 

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6907

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344